Larimar Therapeutics Inc. has filed a prospectus supplement with the Securities and Exchange Commission as part of its public offering of common stock. The company plans to issue and sell 18,750,000 shares at a price of $3.20 per share, with an option for underwriters to purchase an additional 2,812,500 shares. The total net proceeds from the offering, after expenses, are expected to be approximately $64.4 million. The offering is being managed by Leerink Partners LLC, Guggenheim Securities, LLC, Truist Securities, Inc., and William Blair & Company, L.L.C., and is set to close pending customary conditions.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.